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Abstract
The most biologically active metabolite 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) has well known direct effects on osteoblast
growth and differentiation in vitro. The precursor 25-hydroxyvitamin D3 (25(OH)D3) can affect osteoblast function via
conversion to 1,25(OH)2D3, however, it is largely unknown whether 25(OH)D3 can affect primary osteoblast function on its
own. Furthermore, 25(OH)D3 is not only converted to 1,25(OH)2D3, but also to 24R,25-dihydroxyvitamin D3 (24R,25(OH)2D3)
which may have bioactivity as well. Therefore we used a primary human osteoblast model to examine whether 25(OH)D3
itself can affect osteoblast function using CYP27B1 silencing and to investigate whether 24R,25(OH)2D3 can affect osteoblast
function. We showed that primary human osteoblasts responded to both 25(OH)D3 and 1,25(OH)2D3 by reducing their
proliferation and enhancing their differentiation by the increase of alkaline phosphatase, osteocalcin and osteopontin
expression. Osteoblasts expressed CYP27B1 and CYP24 and synthesized 1,25(OH)2D3 and 24R,25(OH)2D3 dose-dependently.
Silencing of CYP27B1 resulted in a decline of 1,25(OH)2D3 synthesis, but we observed no significant differences in mRNA
levels of differentiation markers in CYP27B1-silenced cells compared to control cells after treatment with 25(OH)D3. We
demonstrated that 24R,25(OH)2D3 increased mRNA levels of alkaline phosphatase, osteocalcin and osteopontin. In addition,
24R,25(OH)2D3 strongly increased CYP24 mRNA. In conclusion, the vitamin D metabolites 25(OH)D3, 1,25(OH)2D3 and
24R,25(OH)2D3 can affect osteoblast differentiation directly or indirectly. We showed that primary human osteoblasts not
only respond to 1,25(OH)2D3, but also to 24R,25(OH)2D3 by enhancing osteoblast differentiation. This suggests that
25(OH)D3 can affect osteoblast differentiation via conversion to the active metabolite 1,25(OH)2D3, but also via conversion
to 24R,25(OH)2D3. Whether 25(OH)D3 has direct actions on osteoblast function needs further investigation.
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Introduction
Vitamin D deficiency, a common condition in the elderly
population, has been associated to numerous skeletal health
problems. Vitamin D deficiency causes a decrease of calcium
absorption from the intestines and secondary hyperparathyroidism
which leads to bone loss, osteoporosis and mineralization defects in
the long term [1]. Vitamin D status is determined by the
measurement of the metabolite 25-hydroxyvitamin D3 (25(OH)D3)
[2], which is the major circulating form of vitamin D. The
metabolite 25(OH)D3 is metabolized in the kidney by the enzyme
1a-hydroxylase (CYP27B1) into the biologically most active
metabolite 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) [3], which
is the classical pathway for vitamin D activation. Both 25(OH)D3
and 1,25(OH)2D3 are metabolized by the enzyme 24-hydroxylase
(CYP24), responsible for the first step in the inactivation process,
to respectively 24R,25-dihydroxyvitamin D3 (24R,25(OH)2D3)
and 1,24R,25-trihydroxyvitamin D3 (1,24R,25(OH)3D3) [4]. In
addition, alternative pathways for vitamin D activation have been
described, and one of such is the CYP11A1-mediated pathway [5].
This pathway for activation of vitamin D has been demonstrated
in placentas ex utero, adrenal glands ex vivo and in cultured
epidermal keratinocytes and colonic Caco-2 cells [6,7]. Hydro-
xyvitamin D derivatives synthesized by the action of CYP11A1 not
only act on the vitamin D receptor (VDR), but also on the retinoic
acid related receptors a and c (RORa and RORc) [8].
The metabolite 1,25(OH)2D3 exerts its function by binding to
the VDR which is present in numerous tissues, including bone
tissue [3]. Bone formation is affected by 1,25(OH)2D3 both in an
indirect and direct manner. Indirect effects of 1,25(OH)2D3 occur
through stimulation of intestinal calcium absorption required for
the maintenance of normal serum calcium levels and bone
mineralization [3]. Direct effects of 1,25(OH)2D3 on osteoblasts
have been demonstrated in vitro. These in vitro studies show that
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1,25(OH)2D3 decreases osteoblast proliferation and stimulates
osteoblast differentiation by increasing collagen type I synthesis
and by secreting several non-collagenous proteins, for example
osteocalcin and osteopontin [9]. The metabolite 1,25(OH)2D3 also
increases the alkaline phosphatase (ALP) activity and the
mineralization of bone matrix synthesized by human osteoblasts
[10–12].
While the effects of 1,25(OH)2D3 on human osteoblasts are
well-known, fewer studies have focused on the response of human
osteoblasts to the precursor 25(OH)D3. Van Driel et al [12] have
shown that 25(OH)D3 increases the ALP activity, the osteocalcin
expression, and the early phase of mineralization in the human
SV-HFO cell line. In primary osteoblasts, 25(OH)D3 inhibits the
proliferation, stimulates the expression of osteocalcin and
osteopontin, and increases the mineralization [13]. The actions
of 25(OH)D3 on human osteoblasts are thought to take place after
its conversion to 1,25(OH)2D3, since osteoblasts express 1a-
hydroxylase and are capable of synthesizing 1,25(OH)2D3 from
25(OH)D3 [12–14]. Locally synthesized 1,25(OH)2D3 is thought
to act in an autocrine or paracrine manner to regulate osteoblast
proliferation and differentiation [12,13]. However, it is largely
unknown whether, in addition to the effects of 25(OH)D3 that
occur via hydroxylation to 1,25(OH)2D3, 25(OH)D3 can affect
primary osteoblast function on its own.
In addition to 1a-hydroxylase, osteoblasts express 24-hydroxy-
lase [12,13] and have the capability to synthesize 24R,25(OH)2D3
from 25(OH)D3 [14]. The metabolite 24R,25(OH)2D3 was
originally thought to be inactive, however, several in vivo and
in vitro studies support 24R,25(OH)2D3 bioactivity in bone tissue.
In chickens, 24R,25(OH)2D3 in combination with 1,25(OH)2D3
treatment promotes fracture healing [15]. In addition, CYP24
knockout mice demonstrate a delayed fracture healing [16].
In vitro, 24R,25(OH)2D3 has positive actions on SV-HFO
osteoblast differentiation by increasing ALP activity, osteocalcin
secretion and matrix mineralization [17]. These findings suggest
that primary human osteoblasts not only respond to the active
metabolite 1,25(OH)2D3 but also to 24R,25(OH)2D3.
The aim of this research was to determine the effects of
25(OH)D3 on primary human osteoblast proliferation and
differentiation, compared to 1,25(OH)2D3. To examine whether
these effects of 25(OH)D3 occur through hydroxylation to
1,25(OH)2D3 we silenced CYP27B1 expression. However, osteo-
blasts synthesize not only 1,25(OH)2D3 from 25(OH)D3, but also
24R,25(OH)2D3 from 25(OH)D3. Therefore we hypothesized that
the effects of 25(OH)D3 not only occurred through conversion to
1,25(OH)2D3 but also to 24R,25(OH)2D3.
Materials and Methods
Primary human osteoblast culture
Primary human osteoblasts were isolated from redundant
trabecular bone fragments obtained from healthy donors under-
going pre-implant bony reconstruction of the mandible or maxilla
with autologous bone from the anterior iliac crest. The donor
group consisted of 11 males and 12 females with a mean age of
49.3618.6 years. The protocol was approved by the Medical
Ethical Review Board of the VU University Medical Center,
Amsterdam, the Netherlands, and all donors gave their written
informed consent.
A modification of the methods of Beresford and Marie [18,19]
was used. Shortly, the trabecular bone fragments were minced into
small pieces and washed extensively with phosphate buffered
saline (PBS). The bone pieces were treated with 2 mg/ml
collagenase type II (300 U/mg; Worthington Biochemical Cor-
poration, Lakewood, NJ, USA) for two hours in a shaking
waterbath at 37uC. The pieces were placed in culture flasks with
Dulbecco’s Modified Eagle Medium: Nutrient Mixture F-12
(DMEM/F12; GIBCO, Life technologies) supplemented with
10% Fetal Clone I (HyClone, Thermo Fisher Scientific), 100 U/
ml penicillin and 100 mg/ml streptomycin (GIBCO, Life technol-
ogies), 1.25 mg/ml fungizone (GIBCO, Life technologies) and
incubated at 37uC and 5% CO2. Medium was changed twice a
week until cells reached confluence.
Primary human osteoblast treatments
The vitamin D metabolites 25(OH)D3, 1,25(OH)2D3 and
24R,25(OH)2D3 were obtained from Sigma-Aldrich. Primary
human osteoblasts were treated with or without different vitamin
D concentrations as indicated in the figure legends.
To enable differentiation, primary human osteoblasts were
cultured in osteogenic medium. Osteogenic medium consisted of
complete medium with 10 mmol/L b-glycerophosphate (Sigma-
Aldrich), 10 nmol/L dexamethasone (Sigma-Aldrich) and 50 mg/
ml ascorbic acid (Sigma-Aldrich).
All experiments were performed in complete medium with 5%
Fetal Clone I unless otherwise stated and all conditions, including
treated and control groups, contained 0.1% ethanol.
Proliferation
Primary human osteoblasts of the first passage were plated out
in a 96 wells plate at a density of 4.000 cells/well. After 24 hours
cells were exposed to medium with 25(OH)D3 (0, 100, 200 or
400 nmol/L) or 1,25(OH)2D3 (0, 1, 10 or 100 nmol/L). Medium
was replaced every 3 days by complete medium with or without
25(OH)D3 or 1,25(OH)2D3. The proliferation of primary human
osteoblasts was measured at day 3 and 6 using the XTT Cell
Proliferation Kit (Roche Diagnostics) according to the manufac-
turer’s protocol. Briefly, cells were incubated with the XTT
solution at 37uC, whereby the viable cells formed an orange
formazan dye by cleaving the yellow tetrazolium salt XTT. After 2
hours the orange formazan solution was quantified by a
photospectrometer (Berthold Technologies) at 450 nm.
Differentiation
Primary human osteoblasts of the first or second passage were
seeded into a 12 wells plate at a cell density of 40.000 cells/well.
Cells were allowed to attach to the well for 24 hours before
medium was changed to osteogenic medium with 25(OH)D3 (0 or
400 nmol/L) or 1,25(OH)2D3 (0 or 100 nmol/L). Medium was
replaced every 3 or 4 days by complete medium with or without
25(OH)D3 or 1,25(OH)2D3. Culture medium was collected at day
3, 7, 10 and 14 of the differentiation culture and cell lysates were
prepared for the measurement of osteoblast markers.
Procollagen type I aminoterminal propeptide (P1NP) was
measured in culture medium using the UniQ PINP radioimmu-
noassay (Orion Diagnostica). The interassay variation was ,8%
over the whole concentration range.
ALP activity was measured in cell lysate that was made by
scraping the cells in PBS-0.1% triton [12], and by sonificating of
the lysate two times for 30 seconds at 50 Hz. ALP activity was
measured by the ALP IFCC liquid assay (Roche Diagnostics),
performed on a Modular analyzer (Roche Diagnostics). ALP
activity was adjusted for total protein, measured by the BCA
protein assay (Thermo Fisher Scientific) according to the
manufacturer’s protocol.
Osteocalcin was measured in culture medium using an enzyme
immunoassay (Biosource). Interassay variation was 15% at a level
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of 0.5 nmol/L, 8% at a level of 2 nmol/L and 9% at a level of
8 nmol/L.
RNA isolation and real time RT-PCR
For RNA experiments primary human osteblasts of the first or
second passage were seeded into a 12 wells plate at a cell density of
40.000 cells/well. Medium was changed after 24 hours and
primary human osteoblasts were treated with different vitamin D
metabolites as indicated in the figure legends. Total RNA isolation
of primary osteoblasts was performed using the RNeasy Mini Kit
(Qiagen) according to the manufacturer’s protocol. For removing
residual DNA amounts an additional on-column DNA treatment
was accomplished during the RNA isolation procedure. Total
RNA concentration was measured with the Nanodrop spectro-
photometer (Nanodrop Technologies).
RNA was reverse transcribed from 100 ng total RNA in a 20 ml
reaction mixture containing 5 mmol/L MgCl2 (Eurogentec), 1X
RT buffer (Promega), 1 mmol/L dATP, 1 mmol/L dCTP,
1 mmol/L dGTP, 1 mmol/L dTTP (Roche Diagnostics),
1 mmol/L Betaı¨ne, 10 ng/ml random primer, 0.4 U/ml RNAsin
(Promega) and 5 U/ml M-MLV RT-enzym (Promega). The PCR
reaction of total 25 ml contained 3 ml cDNA, 300 nmol/L reverse
and forward primer (table 1) and SYBR Green Supermix (Bio-
Rad). The PCR was performed on an iCycler iQ Real-Time PCR
Detection System (Bio-Rad): 3 minutes at 95uC, 40 cycli consisting
of 15 seconds at 95uC and 1 minute at 60uC. The relative gene
expression was calculated by the 22DCt method and TATA
binding protein (TBP) was used as housekeeping gene.
siRNA transfection
Silencing RNA was carried out to suppress CYP27B1 mRNA.
Knockdown was performed using CYP27B1 SMART pool and
the negative control ON-TARGET plus SMART pool (Thermo
Fisher Scientific). Primary human osteoblasts of the first passage
were electroporated with the Microporator Pipetype Electropora-
tion System (Digital Bio, Hopkinton, MA, USA) using 1 pulse of
1200 V for 40 ms. After electroporation, 100.000 cells were
seeded in a 24 wells plate in DMEM/F12 with 10% fetal clone I.
Two days after electroporation of the cells, total RNA was isolated
to determine CYP27B1 knockdown. Four days after the electro-
poration treatment, cells were incubated in complete medium with
25(OH)D3 (0 or 400 nmol/L) for 3 days. Complete medium was
collected and stored at 220uC until 1,25(OH)2D3, 25(OH)D3 and
24R,25(OH)2D3 measurements. Cells were lysed and stored at 2
80uC until total RNA isolation.
1,25(OH)2D3, 25(OH)D3 and 24R,25(OH)2D3
measurements
Primary human osteoblasts were seeded into a 6 wells plate with
a cell density of 500.000 cells/well. High bone cell density was
used to raise the 1,25(OH)2D3 concentrations above the detection
levels. After 24 hours, cells were incubated in medium consisting of
DMEM/F12, 0.2% BSA, 100 U/ml penicillin, 100 mg/ml strep-
tomycin, 1.25 mg/ml fungizone and 25(OH)D3 (0, 100, 200, 400
or 1.000 nmol/L). Medium was collected after 24 hours exposure
of osteoblasts to 25(OH)D3.
The metabolite 1,25(OH)2D3 was measured in non-conditioned
and conditioned medium using a radioimmunoassay (IDS). Cross
reactivity with 25(OH)D3 and 24R,25(OH)2D3 was 0.1% and ,
0.01% respectively. Intra-assay variation was 8% at a level of
25 pmol/L and 9% at a level of 70 pmol/L, and interassay
variation was 11% at a concentration of 25 and 70 pmol/L.
The metabolites 25(OH)D3 and 24R,25(OH)2D3 were analyzed
in non-conditioned and conditioned medium using a liquid
chromatography-tandem mass spectrometry (LC-MS/MS) meth-
od. Briefly, samples were incubated with deuterated internal
vitamin D standards (d6–25(OH)D3 and d6-24R,25(OH)2D3) and
protein-precipitated using acetonitrile. Supernatant was, after
PTAD derivatization, purified using a Symbiosis online solid phase
extraction (SPE) system (Spark Holland, Emmen, the Nether-
lands), followed by detection with a Quattro Premier XE tandem
mass spectrometer (Waters Corp., Milford, MA). Intra-assay
variation of 25(OH)D3 was 9.6%, 6.0% and 8.5% at a level of
58, 191 and 516 nmol/L, respectively. Intra-assay variation of
Table 1. Primer sequence.
Gene Primer sequence (59- 39)
CYP27B1 Forward: TGGCCCAGATCCTAACACATTT
Reverse: GTCCGGGTCTTGGGTCTAACT
CYP24 Forward: CAAACCGTGGAAGGCCTATC
Reverse: AGTCTTCCCCTTCCAGGATCA
Vitamin D receptor (VDR) Forward: GGACGCCCACCATAAGACCTA
Reverse: CTCCCTCCACCATCATTCACA
Alkaline phosphatase (ALP) Forward: CCACGTCTTCACATTTGGTG
Reverse: GCAGTGAAGGGCTTCTTGTC
Collagen type 1a1 (COL1a1) Forward: GTGCTAAAGGTGCCAATGGT
Reverse: ACCAGGTTCACCGCTGTTAC
Osteocalcin Forward: GGCGCTACCTGTATCAATGG
Reverse: TCAGCCAACTCGTCACAGTC
Osteopontin Forward: TTCCAAGTAAGTCCAACGAAAG
Reverse: GTGACCAGTTCATCAGATTCAT
TATA binding protein (TBP) Forward: GGTCTGGGAAAATGGTGTGC
Reverse: GCTGGAAAACCCAACTTCTG
doi:10.1371/journal.pone.0110283.t001
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24R,25(OH)2D3 was 5.4% and 9.1% at a level of 46 and
150 nmol/L, respectively.
Statistical analyses
Data were presented as mean 6 SEM. Differences between 2
groups were assessed using Wilcoxon signed rank test. Differences
between 3 or more groups were assessed using Friedman test
followed by Dunn’s post hoc test. A p-value,0.05 was considered
to be significant (*p,0.05, **p,0.01, ***p,0.001).
Results
Effects of 1,25(OH)2D3 and 25(OH)D3 on osteoblast
proliferation
Primary human osteoblasts were cultured in the presence of
1,25(OH)2D3 or 25(OH)D3 for 6 days to compare the effects of
these metabolites on the proliferation. Both 1,25(OH)2D3 (Fig. 1A)
and 25(OH)D3 (Fig. 1B) significantly decreased the proliferation
after 3 and 6 days of treatment. The reduction of the proportion of
viable cells was found to be 28% (p,0.01) and 47% (p,0.01) in
the presence of 100 nmol/L 1,25(OH)2D3 compared to control
cultures at day 3 and 6 respectively. The metabolite 25(OH)D3
decreased the proliferation of primary human osteoblasts after 3
and 6 days of treatment at a concentration of 400 nmol/L. The
reduction of the proportion of viable cells was 12% (p,0.01) and
28% (p,0.05) at day 3 and 6 respectively compared to control
cultures.
Effects of 1,25(OH)2D3 and 25(OH)D3 on osteoblast
differentiation
Primary human osteoblasts were cultured in osteogenic medium
containing 1,25(OH)2D3 or 25(OH)D3 for 14 days to compare the
effects of these metabolites on the differentiation. Both
1,25(OH)2D3 (Fig. 2A) and 25(OH)D3 (Fig. 2B) stimulated the
ALP activity during differentiation. The metabolite 1,25(OH)2D3
increased ALP activity at day 3 (332%; p,0.05) and 10 (238%;
p,0.05) compared to control cultures. The metabolite 25(OH)D3
increased ALP activity at day 3 (369%; p,0.05), 7 (326%; p,
0.05) and 14 (146%; p,0.05) compared to control cultures. P1NP
secretion was decreased by 1,25(OH)2D3 (Fig. 2C) at day 10 (47%;
p,0.05) and 14 (65%; p,0.05) compared to control cultures, but
P1NP secretion was not significantly affected by 25(OH)D3
(Fig. 2D). Osteocalcin secretion was markedly enhanced by both
1,25(OH)2D3 (Fig. 2E) and 25(OH)D3 (Fig. 2F). The metabolite
1,25(OH)2D3 stimulated the secretion at day 3 (p,0.05), whereas
25(OH)D3 increased the secretion at day 10 (p,0.05).
Figure 3 demonstrates effects of 1,25(OH)2D3 or 25(OH)D3 on
mRNA levels of genes involved in primary human osteoblast
differentiation. ALP mRNA levels (Fig. 3A) were stimulated by
both metabolites. The metabolite 1,25(OH)2D3 increased ALP
mRNA levels at a concentration of 100 nmol/L (203%; p,0.01)
and 25(OH)D3 increased ALP mRNA at a concentration of
200 nmol/L (191%; p,0.05) and 400 nmol/L (209%; p,0.05).
Significant effects of 1,25(OH)2D3 or 25(OH)D3 on COL1a1
mRNA levels (Fig. 3B) were not observed. Osteocalcin mRNA was
increased by 10 nmol/L (2147%; p,0.05) and 100 nmol/L
1,25(OH)2D3 (3289%; p,0.01) and by 200 nmol/L (2100%; p,
0.01) and 400 nmol/L 25(OH)D3 (2102%; p,0.01). Osteopontin
mRNA levels (Fig. 3D) were only significantly increased by
25(OH)D3 at a concentration of 400 nmol/L (314%; p,0.05).
Effects of 1,25(OH)2D3 and 25(OH)D3 on VDR, CYP27B1
and CYP24 mRNA levels in primary human osteoblasts
Proliferation and differentiation experiments showed that
primary human osteoblasts were able to respond to
1,25(OH)2D3 and 25(OH)D3. Therefore we examined effects of
both metabolites on mRNA levels of VDR, and metabolizing
enzymes, CYP27B1 and CYP24. VDR mRNA levels (Fig. 4A)
increased in the presence of 100 nmol/L 1,25(OH)2D3 (162%; p,
0.01) and 400 nmol/L 25(OH)D3 (149%; p,0.05). CYP27B1
mRNA (Fig. 4B) did not respond to either 1,25(OH)2D3 or
25(OH)D3. CYP24 mRNA levels (Fig. 4C) increased dose-
dependently in response to 1,25(OH)2D3 at a concentration of
10 nmol/L (p,0.05) and 100 nmol/L (p,0.001). In response to
25(OH)D3, a significant increase of CYP24 mRNA was found at a
concentration of 400 nmol/L (p,0.01).
Synthesis of 1,25(OH)2D3 and 24R,25(OH)2D3 by primary
human osteoblasts
Primary human osteoblasts were cultured in the presence of
increasing concentrations of 25(OH)D3 to study the conversion to
1,25(OH)D3 and 24R,25(OH)2D3. After 24 hours incubation with
100, 200, 400 and 1.000 nmol/L 25(OH)D3, levels of 25(OH)D3
were strongly reduced to respectively 16%, 20%, 29% and 33% of
non-conditioned values (Fig. 5A). The metabolite 1,25(OH)2D3
(Fig. 5B) was produced in a dose-dependent manner after
25(OH)D3 treatment. Mean concentrations of 1,25(OH)2D3 in
medium were 8.8, 41.7, 62.3, 125.6 and 197.3 pmol/L after 24
hours incubation of cells with respectively 0, 100, 200, 400 and
1.000 nmol/L 25(OH)D3. In non-conditioned medium,
1,25(OH)2D3 concentrations ranging from 3.3–60.8 pmol/L were
measured. The metabolite 24R,25(OH)2D3 (Fig. 5C) was also
produced in a dose-dependent manner after 25(OH)D3 treatment.
Figure 1. Effects of 1,25(OH)2D3 and 25(OH)D3 on primary human osteoblast proliferation. Osteoblasts were cultured in the presence of
0, 1, 10 or 100 nM 1,25(OH)2D3 (A) and 0, 100, 200 or 400 nM 25(OH)D3 (B) and the proliferation was quantified at day 3 and 6. Results (mean6 SEM)
are expressed as treatment versus control ratios (time-point 0 was set at 1.0) using cells from 4 (A) or 7 (B) different donors. Results were analysed
using Friedman test followed by Dunn’s post hoc test for each timepoint (*p,0.05, **p,0.01, ***p,0.001).
doi:10.1371/journal.pone.0110283.g001
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Mean concentrations of 24R,25(OH)2D3 in medium were ,3,
16.1, 45.3, 70.2 and 105.4 nmol/L after 24 hours incubation of
cells with respectively 0, 100, 200, 400 and 1.000 nmol/L
25(OH)D3. In non-conditioned medium, 24R,25(OH)2D3 was
not detected (,3 nmol/L).
Effects of 25(OH)D3 on mRNA levels of genes involved in
primary human osteoblast differentiation after CYP27B1
silencing
Silencing of CYP27B1 gene expression was used to examine
whether 25(OH)D3 can directly act on osteoblast function.
Treatment with CYP27B1 siRNA resulted in a 58% reduction
of CYP27B1 mRNA compared to the control culture (p,0.05)
(Fig. 6A). After 25(OH)D3 treatment, the reduction of CYP27B1
mRNA resulted in a decreased 1,25(OH)2D3 synthesis of 30% (p,
0.05) compared to the control culture (Fig. 6B). Levels of
24R,25(OH)2D3 (Fig. 6C) and 25(OH)D3 (Fig. 6D) did not change
in silenced and control cultures. After 72 hours of 25(OH)D3
treatment, the reduction of CYP27B1 mRNA was still 62% in the
absence of 25(OH)D3 and 45% in the presence of 25(OH)D3
(Fig. 6E). No significant differences were seen between mRNA
levels of CYP24 (Fig. 6F), VDR (Fig. 6G), ALP (Fig. 6 H),
osteocalcin (Fig. 6I) and osteopontin (Fig. 6J) in control and
CYP27B1-silenced cells that were exposed to 25(OH)D3.
Effects of 24R,25(OH)2D3 on osteoblast differentiation
In addition to 1,25(OH)2D3, we showed that osteoblasts are able
to synthesize 24R,25(OH)2D3 from the precursor 25(OH)D3. To
examine whether 24R,25(OH)2D3 can act on osteoblast differen-
tiation, primary human osteoblasts were cultured in the presence
Figure 2. Effects of 1,25(OH)2D3 and 25(OH)D3 on ALP activity, P1NP and osteocalcin secretion by primary human osteoblast.
Osteoblasts were cultured in the presence of 0 or 100 nM 1,25(OH)2D3 and 0 or 400 nM 25(OH)D3 and ALP activity (A and B respectively), P1NP (C
and D respectively) and osteocalcin secretion (E and F respectively) were measured at day 3, 7, 10 and 14 of the differentiation. Results are expressed
as mean 6 SEM using cells from 5 different donors. Results were analyzed using Wilcoxon signed rank test for each timepoint (*p,0.05, **p,0.01,
***p,0.001).
doi:10.1371/journal.pone.0110283.g002
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of 24R,25(OH)2D3. After 72 hours, 24R,25(OH)2D3 did not affect
COL1a1 mRNA levels (Fig. 7A), but 400 nmol/L
24R,25(OH)2D3 increased ALP (137%; p,0.05) (Fig. 7B), osteo-
calcin (6182%; p,0.01) (Fig. 7C) and osteopontin (387%; p,0.05)
(Fig. 7D) mRNA levels.
Effects of 24R,25(OH)2D3 on VDR, CYP27B1 and CYP24
mRNA levels in primary human osteoblasts
We did not observe effects of 24R,25(OH)2D3 on mRNA levels
of VDR (Fig. 8A) and CYP27B1 (Fig. 8B). The metabolite
24R,25(OH)2D3 highly induced CYP24 mRNA (Fig. 8C) levels
in cells treated with 400 nmol/L 24R,25(OH)2D3 (p,0.001).
Discussion
This in vitro study shows the response of primary human
osteoblasts to 25(OH)D3, 1,25(OH)2D3 and 24R,25(OH)2D3.
Primary human osteoblasts responded to 25(OH)D3 by reducing
their proliferation and enhancing their differentiation, similarly to
1,25(OH)2D3. We hypothesized that these 25(OH)D3 actions on
osteoblast function occurred not only through hydroxylation to
1,25(OH)2D3, but possibly also through hydroxylation to
24R,25(OH)2D3. We could demonstrate that primary human
osteoblasts expressed CYP27B1 and CYP24 and were capable to
synthesize respectively 1,25(OH)2D3 as well as 24R,25(OH)2D3
from 25(OH)D3. Moreover, we showed that 24R,25(OH)2D3
increased mRNA levels of genes involved in primary human
osteoblast differentiation.
The prohormone 25(OH)D3 has comparable effects to
1,25(OH)2D3 on growth and differentiation of primary osteoblasts.
The metabolites 25(OH)D3 and 1,25(OH)2D3 reduced osteoblast
proliferation and stimulated the differentiation as shown by
increasing ALP activity (mRNA and protein) and osteocalcin
secretion (mRNA and protein). Our study confirms previous
studies in human osteoblastic cell lines and primary osteoblasts
[12,13,20].
The effects of 25(OH)D3 on proliferation and differentiation
likely occur through hydroxylation to 1,25(OH)2D3 [12,13], since
we and others demonstrated that osteoblasts are able to synthesize
the active metabolite 1,25(OH)2D3 after exposure to the precursor
25(OH)D3 [12–14]. The consideration that effects of 25(OH)D3
occur through conversion to 1,25(OH)2D3 is supported by several
in vitro blocking studies. In CYP27B1-silenced HOS cells, a
human osteoblast cell line, it has been shown that exposure to
25(OH)D3 leads to a decline of osteonectin and CYP24 mRNA
expression compared to control cells [21]. In human marrow
Figure 3. Effects of 1,25(OH)2D3 and 25(OH)D3 on mRNA levels of genes involved in primary human osteoblast differentiation.
Osteoblasts were cultured in the presence of 0, 1, 10 and 100 nM 1,25(OH)2D3 or 0, 100, 200 or 400 nM 25(OH)D3 for 10 days in osteogenic medium
and mRNA levels of ALP (A), COL1a1 (B), osteocalcin (C) and osteopontin (D) were determined. Results (mean 6 SEM) are expressed as treatment
versus control ratios (control was set at 1.0; dashed line) using cells from 5 different donors. Results were analysed using Friedman test followed by
Dunn’s post hoc test (*p,0.05, **p,0.01, ***p,0.001).
doi:10.1371/journal.pone.0110283.g003
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stromal cells differentiated to osteoblasts, CYP27B1 is reported to
be necessary for the antiproliferative and prodifferentiation effects
of 25(OH)D3 [20]. Furthermore, in SV-HFO osteoblasts, ketoco-
nazole almost complete blocked the effects of 25(OH)D3 on
osteocalcin mRNA levels [12].
In our study, CYP27B1-silencing resulted in a decline of
1,25(OH)2D3 synthesis by primary osteoblasts. Despite this
reduction, no significant differences in mRNA levels of differen-
tiation markers were seen in CYP27B1-silenced cells compared to
control cells after treatment with 25(OH)D3. It is likely that
Figure 4. Effects of 1,25(OH)2D3 and 25(OH)D3 on VDR,
CYP27B1 and CYP24 mRNA levels in primary human osteo-
blast. Osteoblasts were cultured in the presence of 0, 1, 10 and 100 nM
1,25(OH)2D3 or 0, 100, 200 and 400 nM 25(OH)D3 for 24 hours and
mRNA levels of VDR (A), CYP27B1 (B) and CYP24 (C) were determined.
Results (mean 6 SEM) are expressed as treatment versus control ratios
(control was set at 1.0; dashed line) using cells from 5 or 6 different
donors. Results were analysed using Friedman test followed by Dunn’s
post hoc test (*p,0.05, **p,0.01, ***p,0.001).
doi:10.1371/journal.pone.0110283.g004
Figure 5. Synthesis of 1,25(OH)2D3 and 24R,25(OH)2D3 by
primary human osteoblasts. Osteoblasts were cultured in the
presence of 0, 100, 200, 400 and 1.000 nM 25(OH)D3 for 24 hours and
25(OH)D3 (A) 1,25(OH)2D3 (B) and 24R,25(OH)2D3 (C) levels were
measured in non-conditioned and conditioned culture medium. Results
are expressed as mean 6 SEM using cells from 3 different donors.
doi:10.1371/journal.pone.0110283.g005
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CYP27B1-silenced cells produced sufficient 1,25(OH)2D3 to
induce a response. It is also possible that 25(OH)D3 affected
osteoblast function through hydroxylation to 24R,25(OH)2D3.
Levels of 24R,25(OH)2D3 were present in control and silenced
cultures. Moreover, we showed that osteoblast cultures exposed to
24R,25(OH)2D3 had increased mRNA levels of ALP, osteocalcin
and osteopontin. These results indicate a role for 24R,25(OH)2D3
in osteoblast differentiation. This is in line with previous research
in the human osteoblast cell line SV-HFO in which
24R,25(OH)2D3 stimulated ALP activity and osteocalcin secretion
by binding to the VDR [17]. Our results are also supported by a
study in human mesenchymal stem cells, in which
24R,25(OH)2D3 enhances the osteoblastic differentiation by
increasing ALP activity, osteocalcin mRNA levels and calcium
mineralization of matrix [22]. In addition, our results are
supported by a study in primary human osteoblasts that found
increased osteocalcin production after 24R,25(OH)2D3 treatment
[23]. However, due to incomplete CYP27B1 knockdown,
24R,25(OH)2D3 effects may be caused by 1a-hydroxylation to
1,24R,25(OH)3D3. The strong reduction of 25(OH)D3 levels in
medium supports the idea that also other metabolites than
1,25(OH)2D3 and 24R,25(OH)2D3 are formed, for example
1,24R,25(OH)3D3. The metabolite 1,24R,25(OH)3D3 is able to
enhance ALP activity, osteocalcin production and mineralization
by SV-HFO osteoblasts [17]. In addition, 1,24R,25(OH)3D3 is
even more potent than 24R,25(OH)2D3 [17].
In addition to the actions of 24R,25(OH)2D3 on mRNA levels
of differentiation genes, 24R,25(OH)2D3 was also able to markedly
enhance mRNA levels of CYP24. This may result in a higher
production of 24R,25(OH)2D3 which suggests that
24R,25(OH)2D3 has the ability to regulate its own synthesis in a
positive way (positive feedback). This is not in line with research
Figure 6. Effects of 25(OH)D3 on mRNA levels of genes involved in primary human osteoblast differentiation after CYP27B1
silencing. CYP27B1-silenced and control cells were incubated in the presence of 0 or 400 nM 25(OH)D3 for 3 days. CYP27B1 knock down was
determined before 25(OH)D3 treatment (A). After 72 hours incubation with 25(OH)D3, we examined levels of 1,25(OH)2D3 (B), 24R,25(OH)2D3 (C) and
25(OH)D3 (D), and mRNA levels of CYP27B1 (E), CYP24 (F), VDR (G), ALP (H), osteocalcin (I) and osteopontin (J) in CYP27B1-silenced and control cells.
Results are expressed as mean6 SEM using cells from 5 different donors. Results were analysed using Friedman test followed by Dunn’s post hoc test
(*p,0.05, **p,0.01, ***p,0.001).
doi:10.1371/journal.pone.0110283.g006
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performed in human mesenchymal stem cells differentiated to
osteoblasts [22]. These osteoblasts decrease their CYP24 mRNA
levels in response to 24R,25(OH)2D3 (at a concentration of
10 nmol/L) [22]. Added concentrations of 24R,25(OH)2D3 may
explain the opposite results, since our results were obtained by
using high 24R,25(OH)2D3 concentrations (400 nmol/L). Fur-
thermore, we showed that 24R,25(OH)2D3, as well as 25(OH)D3
and 1,25(OH)2D3, had no effect on CYP27B1 mRNA levels. In
human mesenchymal stem cells differentiated to osteoblasts,
24R,25(OH)2D3 (at a concentration of 10 nmol/L) decreases
CYP27B1 mRNA and 1,25(OH)2D3 synthesis [22].
Actions of 24R,25(OH)2D3 can take place by activating the
nuclear VDR [17], although the binding affinity of
24R,25(OH)2D3 to the VDR is 100 times less than 1,25(OH)2D3
Figure 7. Effects of 24R,25(OH)2D3 on mRNA levels of genes involved in osteoblast differentiation. Osteoblasts were cultured in the
presence of 0, 100, 200 or 400 nM 24R,25(OH)2D3 and mRNA levels of COL1a1 (A), ALP (B), osteocalcin (C) and osteopontin (D) were determined after
72 hours. Results (mean 6 SEM) are expressed as treatment versus control ratios (control was set at 1.0; dashed line) using cells from 4 different
donors. Results were analysed using Friedman test followed by Dunn’s post hoc test (*p,0.05, **p,0.01, ***p,0.001).
doi:10.1371/journal.pone.0110283.g007
Figure 8. Effects of 24R,25(OH)2D3 on VDR, CYP27B1 and CYP24 mRNA levels in primary human osteoblasts. Osteoblasts were
cultured in the presence of 0, 100, 200 or 400 nM 24R,25(OH)2D3 and mRNA levels of VDR (A), CYP27B1 (B) and CYP24 (C) were determined after 72
hours. Results (mean 6 SEM) are expressed as treatment versus control ratios (control was set at 1.0; dashed line) using cells from 4 different donors.
Results were analysed using Friedman test followed by Dunn’s post hoc test (*p,0.05, **p,0.01, ***p,0.001).
doi:10.1371/journal.pone.0110283.g008
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[24]. In our study, 24R,25(OH)2D3 did not affect VDR mRNA,
while 25(OH)D3 and 1,25(OH)2D3 increased VDR mRNA.
Effects of 24R,25(OH)2D3 effects may be cell and concentration
dependent, because at lower concentrations (10 nmol/L),
24R,25(OH)2D3 can decrease VDR mRNA and protein in human
mesenchymal stem cells differentiated to osteoblasts [22].
The metabolite 25(OH)D3 itself may also be capable to activate
the VDR and to subsequently affect mRNA levels of differenti-
ation genes. This is supported by the in vivo study of Rowling et al
[25] that supraphysiological levels of 25(OH)D3 can affect calcium
and bone metabolism in the absence of its hydroxylation to
1,25(OH)2D3. In this study CYP27B1 knock out mice were fed a
diet high in cholecalciferol which prevented hypocalcemia and
almost rescued skeletal growth [25]. Several in vitro studies also
support the hypothesis that 25(OH)D3 has direct effects on cells.
Curtis [22] showed that 25(OH)D3 stimulates osteoblast mineral-
ization in the presence of the cytochrome P450 inhibitor
ketoconazole. Lou et al [26] showed that 25(OH)D3 is an agonistic
VDR ligand and has direct inhibitory effects on proliferation in
human LNCaP prostate cancer cells. In bovine parathyroid cells,
25(OH)D3 suppressed PTH secretion while 1a-hydroxylase was
inhibited by clotrimazole. Therefore further studies are needed to
clarify whether 25(OH)D3 can directly affect primary human
osteoblasts. Although 25(OH)D3 may activate the VDR, the
binding affinity to the VDR is less for 25(OH)D3 compared to
1,25(OH)2D3. Bouillon [24] reported that the binding affinity for
25(OH)D3 to the VDR is 50 times less than 1,25(OH)2D3.
In bone tissue, 25(OH)D3 metabolism may be beneficial since it
is thought that locally synthesized 1,25(OH)2D3 supports osteo-
blast differentiation and matrix mineralization [12,13,27]. Serum
25(OH)D3 levels serve as substrate for local 25(OH)D3 metabolism
and an adequate vitamin D status may therefore be essential [28].
In addition, low 25(OH)D3 serum levels in the range of deficiency
may be a limiting factor for the synthesis of 1,25(OH)2D3 [29] and
24R,25(OH)2D3, and may result in reduced osteoblast differenti-
ation and thereby a reduction of bone strength.
A limitation of this study is that complete blocking of the
1,25(OH)2D3 synthesis was not achieved in the RNA-silencing
experiments. Therefore the question whether 25(OH)D3 itself is
able to affect osteoblast function, can not be answered. Additional
research is needed to achieve completely blocking of 1,25(OH)2D3
synthesis, for example studies with osteoblasts isolated from bone
from CYP27B1 knock out mice. Furthermore, a critical point in
our primary osteoblast cell culture model is the use of relatively
high concentrations of 25(OH)D3, 1,25(OH)2D3 and
24R,25(OH)2D3 compared to normal serum levels in humans.
Our concentrations of vitamin D metabolites were based on other
studies in literature [12,13], but effects of physiological levels of
vitamin D metabolites on bone formation may be different. Lastly,
in non-conditioned medium relatively high 1,25(OH)2D3 levels
were measured. These levels of 1,25(OH)2D3 levels in non-
conditioned medium are probably caused by cross-reactivity with
25(OH)D3 because of the high doses of 25(OH)D3 used in this
study. However, our study clearly showed increased 1,25(OH)2D3
concentrations in conditioned medium compared to non-condi-
tioned medium, which demonstrates the synthesis of 1,25(OH)2D3
by osteoblasts.
In conclusion, the vitamin D metabolites 25(OH)D3,
1,25(OH)2D3 and 24R,25(OH)2D3 can affect osteoblast differen-
tiation directly or indirectly. The metabolite 25(OH)D3 is
converted to both 1,25(OH)2D3 and 24R,25(OH)2D3, as demon-
strated by measurements in culture medium. We showed that
primary human osteoblasts not only respond to 1,25(OH)2D3, but
also to 24R,25(OH)2D3 by enhancing the differentiation. This
suggests that 25(OH)D3 can affect osteoblast differentiation via
conversion to the active metabolite 1,25(OH)2D3, but also via
conversion to 24R,25(OH)2D3 (direct or indirect via
1,24R,25(OH)3D3). Whether 25(OH)D3 has direct actions on
osteoblast differentiation needs further investigation.
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